Anteris Technologies Global CORP. 8-K Filing

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share AVR The Nasdaq Global Mar

Filing Documents

• ef20060235_8k.htm (8-K) — 28KB
• 0001140361-25-043801.txt ( ) — 157KB
• avr-20251126.xsd (EX-101.SCH) — 4KB
• avr-20251126_lab.xml (EX-101.LAB) — 22KB
• avr-20251126_pre.xml (EX-101.PRE) — 16KB
• ef20060235_8k_htm.xml (XML) — 4KB

02

Item 1.02. Termination of a Material Definitive Agreement . On November 26, 2025, Anteris Technologies Global Corp. (the "Company") notified 4C Medical Technologies, Inc. ("4C") that it was not renewing the Second Amended and Restated Supply and License Agreement, as amended (the "Supply Agreement"), between the Company and 4C, which provided for the supply by the Company to 4C of ADAPT tissue used in 4C's production of medical devices related to transcatheter mitral valve and tricuspid valve regurgitation therapy and granted a limited license to the Company's related sterilization methods in connection with use of ADAPT tissue by 4C in its production of medical devices. The Supply Agreement had a term expiring on June 1, 2026, at which time it would automatically renew for successive one-year terms unless either party provided written notice of non-renewal 180 days prior thereto. The Company will not incur any early termination penalties in connection with its non-renewal of the Supply Agreement. The termination of this contract does not materially impact on the financial results of the Company.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Anteris Technologies Global Corp. Date: December 1, 2025 By: /s/ Wayne Paterson Name: Wayne Paterson Title: Vice Chairman and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR